<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602210</url>
  </required_header>
  <id_info>
    <org_study_id>SCOTCH-SCotCHIS in the UK</org_study_id>
    <nct_id>NCT02602210</nct_id>
  </id_info>
  <brief_title>Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis</brief_title>
  <acronym>SCOTCH;</acronym>
  <official_title>Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study is to investigate the clinical relevance, efficacy and safety of&#xD;
      treating hypotensive cirrhotic patients with suspicion of sepsis and on vasopressors with&#xD;
      low-dose hydrocortisone in order to reverse hemodynamic instability and organ failure and to&#xD;
      decrease mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ample evidence suggests that a significant number of patients (52-77%) with chronic liver&#xD;
      disease develop adrenal insufficiency in case of concomitant sepsis. This condition impairs&#xD;
      hemodynamic integrity and probably worsens often encountered multiorgan failure. Different&#xD;
      groups suggested that treating those patients with corticosteroids gives a faster reversal of&#xD;
      hemodynamic instability and even lowers mortality compared to historical controls. However,&#xD;
      most of the published data are retrospective and comprise small groups of patients. These&#xD;
      data raise the possibility that corticosteroids at stress doses may be beneficial in&#xD;
      hypotensive cirrhotics admitted to the ICU but as yet this has not been subjected to a&#xD;
      large-scale multicentre randomized controlled clinical trial.&#xD;
&#xD;
      The study will be a double-blind, randomized, placebo-controlled, multicenter trial,&#xD;
      involving tertiary intensive care units with expertise in management of patients with&#xD;
      decompensated cirrhosis. Patients who satisfy inclusion criteria and do not present any of&#xD;
      the exclusion criteria at ICU admission will be randomized into two groups:&#xD;
&#xD;
        -  Group A: treated with intravenous hydrocortisone in addition to standard therapy (=&#xD;
           treatment group)&#xD;
&#xD;
        -  Group B: placebo (NaCl 0.9%) treatment in addition to standard treatment (= placebo&#xD;
           group)&#xD;
&#xD;
      If, after adequate fluid resuscitation, patients are still on norepinephrine at a dose of at&#xD;
      least 0,1 mcg/kg/min for at least 4 hours, the patient can be randomized. Study drug can be&#xD;
      started immediately after randomization but no later than 24 h after initiation of&#xD;
      norepinephrine. Patients will receive an intravenous bolus of 50 ml of normal saline&#xD;
      (placebo) or an intravenous bolus of 50 ml of normal saline containing 100 mg of&#xD;
      hydrocortisone (double-blind) that will be followed by a continuous intravenous infusion of&#xD;
      the study drug (hydrocortisone) or placebo. Treatment with study drug (hydrocortisone or&#xD;
      placebo) at initial rate will be maintained until the start of day 4 and gradually&#xD;
      discontinued (reduction of infusion rate with 0.5 ml/h/d) when 1) patients do not require&#xD;
      vasoactive drugs anymore to maintain MAP(mean arterial pressure) &gt; 60 mmHg or &gt; 65 mmHg if&#xD;
      associated with signs of hypoperfusion in spite of ongoing adequate fluid resuscitation or 2)&#xD;
      in any case after a 7-day treatment period.&#xD;
&#xD;
      Investigators, treating physicians, nurses and patients will be blinded to the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low inclusion rate&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival at 28 days analysed from the day of randomisation</measure>
    <time_frame>28days</time_frame>
    <description>survival status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient survival at 90 days analysed from the day of randomization</measure>
    <time_frame>90 days</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality</measure>
    <time_frame>from the date of randomisation until ICU discharge or hospital mortality, whichever came first, up to day 90</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reversal of shock</measure>
    <time_frame>up to day 90</time_frame>
    <description>time in days from start of placebo or active medication to resolution of shock as defined as cessation of continuous vasopressor medication (for &gt; 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reversal of organ failures</measure>
    <time_frame>up to 90 days</time_frame>
    <description>measured with SOFA-score and CLIF (Chronic Liver Failure Consortium)-SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasopressor doses</measure>
    <time_frame>up to 90 days</time_frame>
    <description>administration of vasopressor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasopressor-free days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days without vasopression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation-free days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days without mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for and duration of renal replacement therapy</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days of renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length-of-stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>days of ICU stay , days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acquirement of new infections</measure>
    <time_frame>up to 90 days</time_frame>
    <description>bacterial and/or fungal: defined according to CDC (Centers for Diseases Control) criteria (pneumonia, bacteremia, spontaneous bacterial peritonitis, catheter-related bloodstream infections, skin infections and others)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shock relapse</measure>
    <time_frame>during tapering period until 3 days after end of study drug</time_frame>
    <description>defined as hypotension recurrence during the tapering period or within 3 days of total discontinuation of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically important bleeding</measure>
    <time_frame>up to 90 days</time_frame>
    <description>defined as new melena, new haematemesis or unexplained fall in haemoglobin &gt; 2g/dl (not related to volume expansion). The presence of 'coffee ground' aspirate from nasogastric aspirate will not be considered active GI bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control</measure>
    <time_frame>during ICU stay, up to 10 days</time_frame>
    <description>measured as units of insulin required to attain glycemic levels between 80 - 140 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>episode of hyper- (&gt; 180 mg/dl) or hypoglycemia (&lt; 60 mg/dl)</measure>
    <time_frame>during study treatment period, up to 10 days</time_frame>
    <description>number of episodes of hypo- hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new shock episode</measure>
    <time_frame>during study treatment period, up to 13 days</time_frame>
    <description>hypotension recurrence with need for vasopressor therapy after 3 days of total discontinuation of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of coagulopathy</measure>
    <time_frame>during ICU stay up to 10 days</time_frame>
    <description>assessed by disseminated intravascular coagulopathy (DIC)-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of ICU-acquired weakness</measure>
    <time_frame>during ICU stay, up to 90 days</time_frame>
    <description>occurrence of IC acquired weakness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>solucortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCL 0.9%</intervention_name>
    <description>IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with known or recently diagnosed cirrhosis who&#xD;
&#xD;
               1. are admitted to the ICU because of persistent hypotension or&#xD;
&#xD;
               2. develop persistent hypotension while admitted to the ICU,&#xD;
&#xD;
        secondary to proven or suspected infection, in both cases despite adequate fluid&#xD;
        resuscitation and with persistent need for low-dose norepinephrine to maintain a mean&#xD;
        arterial blood pressure &gt; 60 mmHg or &gt; 65 mmHg if accompanied by signs of hypoperfusion,&#xD;
        are eligible for study entry. The diagnosis of cirrhosis is preferably made by histology or&#xD;
        based on imaging and laboratory findings.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or ≥ 80 years&#xD;
&#xD;
          -  Patients receiving any vasopressor medication for more than 24 h prior to&#xD;
             administration of study drug. Terlipressin initiated for treatment of hepatorenal&#xD;
             syndrome or variceal bleeding is allowed&#xD;
&#xD;
          -  Patients with known hypoadrenalism&#xD;
&#xD;
          -  Active GI bleeding (unless controlled for &gt;72 hours) or hemorrhagic shock.&#xD;
&#xD;
          -  Cardiogenic shock or severe cardiac dysfunction (CI &lt;2 l/min/ m2)&#xD;
&#xD;
          -  Active uncontrolled hepatitis B infection&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Evidence of current malignancy (except hepatocellular carcinoma within transplant&#xD;
             criteria or non-melanocytic skin cancer)&#xD;
&#xD;
          -  Therapy with any corticosteroid (oral or intravenous) in the last 3 months&#xD;
&#xD;
          -  Patients who received etomidate within the past 3 days&#xD;
&#xD;
          -  Severe acute alcoholic hepatitis (biopsy proven)&#xD;
&#xD;
          -  Chronic hemodialysis&#xD;
&#xD;
          -  Severe chronic heart disease (NYHA class III or IV)&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (GOLD III or IV)&#xD;
&#xD;
          -  Severe psychiatric disorder&#xD;
&#xD;
          -  Child-Pugh score C14 -15&#xD;
&#xD;
          -  SOFA score &gt; 16 points at inclusion&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindications for systemic steroids&#xD;
&#xD;
          -  Refusal to consent&#xD;
&#xD;
          -  Patients who cannot provide prior informed consent and when there is documented&#xD;
             evidence that the patient has no legal surrogate decision maker and it appears&#xD;
             unlikely that the patient will regain consciousness or sufficient ability to provide&#xD;
             delayed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Meersseman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Wilmer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Fernandez, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Giovanni Battista Hospital</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>liver</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>hypotension</keyword>
  <keyword>sepsis</keyword>
  <keyword>cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

